Niemann-Pick C (NPC) disease is due to loss of NPC1 or NPC2 protein function that is required for unesterified cholesterol transport from the endosomal/lysosomal compartment. Though lung involvement is a recognized characteristic of Niemann-Pick type C disease, the pathological features are not well understood. We investigated components of the surfactant system in both NPC1 mutant mice and felines and in NPC2 mutant mice near the end of their expected life span. Histological analysis of the NPC mutant mice demonstrated thickened septae and foamy macrophages/leukocytes. At the level of electron microscopy, NPC1-mutant type II cells had uncharacteristically larger lamellar bodies (LB, mean area 2-fold larger), while NPC2-mutant cells had predominantly smaller lamellar bodies (mean area 50% of normal) than wild type. Bronchoalveolar lavage from NPC1 and NPC2 mutant mice had an approx. 4-fold and 2.5-fold enrichment in phospholipid, respectively, and an approx. 9-fold and 35-fold enrichment in cholesterol, consistent with alveolar lipidosis. Phospholipid and cholesterol also were elevated in type II cell LBs and lung tissue while phospholipid degradation was reduced. Enrichment of surfactant protein-A in the lung and surfactant of the mutant mice was found. Immunocytochemical results showed that cholesterol accumulated in the LBs of the type II cells isolated from the affected mice. Alveolar macrophages from the NPC1 and NPC2 mutant mice were enlarged compared to those from wild type mice and were enriched in phospholipid and cholesterol. Pulmonary features of NPC1 mutant felines reflected the disease described in NPC1 mutant mice. Thus, with the exception of lamellar body size, the lung phenotype seen in the NPC1 and NPC2 mutant mice were similar. The lack of NPC1 and NPC2 proteins resulted in a disruption of the type II cell surfactant system contributing to pulmonary abnormalities.
Introduction
Niemann-Pick disease type C (NPC) is an autosomal recessive lysosomal storage disorder marked by excess intralysosomal cholesterol, progressive neurodegeneration and hepatosplenomegaly that has no effective approved treatments [1] . Loss of NPC1 or NPC2 protein function results in Niemann-Pick type C1 or type C2 disease, respectively. The two types of NPC disorders are thought to be clinically and biochemically indistinguishable, with reports of pulmonary involvement in both with alveolar proteinosis and foamy macrophages, although NPC2 disease seems to have a more severe phenotype [2, 3, 4] . Whereas the pulmonary disease can be acute, the surfactant system in Niemann-Pick disease has not been fully described in detail. There has been a case report of a patient with a frameshift mutation in NPC2 and reduced NPC2 protein levels. The bronchoalveolar lavage fluid from this patient was analyzed and a marked accumulation of surfactant phospholipid and cholesterol was shown [2] . NPC2 hypomorph mice and patients with NPC2 disease develop alveolar periodic acid-Schiffpositive material, indicative of pulmonary alveolar proteinosis (PAP) [2] . PAP is a rare lung disorder characterized by abnormal accumulation of surfactant with little to no inflammation and fibrosis.
The most common mutations associated with NPC disease (95% of cases) are in the NPC1 gene with the affected patients demonstrating a broad clinical spectrum [5] . However, lung abnormalities are not well characterized. Animal models of NPC1 disease include mice and felines. The pathology of the lung in Npc1 nih/nih mice demonstrated vacuoles in type I and endothelial cells and foamy alveolar macrophages [6] . Cholesterol and phospholipid accumulation in the lung organ of the Npc1 mice has been documented but surfactant was not analyzed [6, 7, 8] . The feline model of NPC1 disease is a domestic short-haired cat with a spontaneous missense mutation (C955S) in NPC1. The feline NPC1 mutation is orthologous to the most common mutation in juvenile-onset patients [9] . The cats demonstrate progressive neurologic symptoms with dysmetria, ataxia and whole body tremor and the liver and spleens have significantly higher levels of unesterified cholesterol. Cultured feline fibroblasts demonstrate perinuclear accumulation of cholesterol utilizing the same assay employed in the identification of NPC disease in humans [10] .
Pulmonary abnormalities have not been examined. The pathologic changes in the mouse and human lung with NPC disease implicate a dysfunction in type II cells, the primary surfactant secreting cell.
Pulmonary surfactant, produced by type II alveolar cells, performs the critical role of reducing surface tension in the alveoli. Cholesterol is the most abundant neutral lipid in surfactant, contributing 5-10% weight by volume, with the rest made up of phospholipids and protein [11] . Cholesterol influences the stability and surface viscosity of surfactant making it an important component in the determination of surfactant physical properties [12] . Elevated (.20%) cholesterol inhibits surfactant function, contributing to surfactant dysfunction in ARDS and acute lung injury [13, 14] . One model suggests that cholesterol accumulates at the surfactant-air interface, interfering with the formation of stacked bilayer patches, structures that contain surfactant lowering protein SP-C [15] . Turnover of surfactant phospholipid is well studied while little is known about the molecular mechanisms regulating surfactant cholesterol. Most lung cholesterol is derived from plasma lipoproteins and radioactive tracer studies demonstrated the delivery of labeled cholesterol from lipoproteins to lamellar bodies and, subsequently, to surfactant secreted into the alveolar space [16] . Type II pneumocytes synthesize and store surfactant in lamellar bodies (LBs), lysosome-related organelles, prior to secretion into the airspace. The Niemann-Pick C pathway has been shown to regulate the removal of low density lipoprotein (LDL)-derived cholesterol from the lumen of the late endosome/ lysosome system to the cytosolic compartment [17, 18] . We hypothesized that this pathway may play a role in surfactant cholesterol transport since we showed that the Niemann-Pick C (NPC) proteins, NPC1 and NPC2 were present in lamellar bodies [19] . NPC1 is an endo-lysosomal transmembrane protein that contains a sterol-sensing domain [17] . NPC2 is a 132 amino acid soluble, mannose-6-phosphate targeted lysosomal protein that also is found in the alveolar space [18, 19] . A current model suggests that NPC2 binds the unesterified cholesterol released after the hydrolysis of LDL cholesteryl ester by lysosomal acid lipase. The NPC2 protein then docks to the second luminal domain of NPC1 and cholesterol is exchanged between NPC2 and the N-terminal domain of NPC1 [20, 21, 22] . NPC1 protein directs the egress of cholesterol from the lysosome through an unknown mechanism, possibly involving the oxysterol-binding protein-related protein 5 [23] . Inhibition of the NPC pathway in isolated type II cells with pharmacological inhibitor U18666A leads to accumulation of cholesterol in the lumen of lamellar bodies, suggesting that the NPC pathway plays a role in regulating lamellar body cholesterol [19] .
Reports on the morphology of type II cells in lungs of patients or animal models of NPC deficiency describe the pneumocytes to be ''unremarkable'' [6] . However, due to the cholesterol accumulation in the lung tissue of NPC1-deficient mice [24] the marked pulmonary lipid accumulation in the NPC2 patient [2] , and the presence of NPC1 and NPC2 in the lamellar bodies of type II cells [19] , we hypothesized that mutations in either NPC1 or NPC2 would result in a dysfunction in pneumocytes and adversely alter the surfactant system. This study was undertaken to define the effects of disorders in cholesterol transport due to the absence of NPC proteins on type II cell homeostasis. We have employed detailed histological and biochemical analysis of alveolar type II cells, macrophages, lamellar bodies, and surfactant in NPC1 and NPC2 mutant mice and NPC1 mutant felines. The NPC1 and NPC2 pulmonary diseases were compared to determine whether any pathologic characteristics differed between them. As treatments for the central nervous system dysfunctions in NPC disease are making progress, a more complete understanding of the lung pathogenesis will aid in the assessment of new therapies specific for the pulmonary components of the disease.
Materials and Methods

Ethics Statement
The mice and felines were housed under the National Institutes of Health and USDA guidelines for the care and use of animals in research. The University of Pennsylvania Institutional Animal Care and Use Committee (IACUC) approved all experimental protocols.
Animals
Mice. Npc1 nih/nih and Npc2 hypomorph mice on a BALB/c background were obtained as a gift from Dr. Peter Lobel. Both types of mice are established models of NPC disease. The Npc1 mouse defect arose due to a spontaneous mutation in mouse chromosome 18 [8] . 24 base pairs of unidentified sequence replaced 44 base pairs of the wild type sequence, resulting in a frame shift and premature truncation of the open reading frame [25] . The Npc2 mutant mice were produced by Sleat, et al. and contain an aberrant recombination event such that the targeted allele has an additional repeat of intron 1 and replacement of amino acid cysteine 42 with a stop codon [26] . As a result, immuno-detection found little to no NPC2 expression in most tissues. The genotypes of the Npc1 and Npc2 mice were determined by PCR of genomic DNA from tail tips. The primer pairs have been previously described [26] . Mice were housed in a pathogenfree animal facility at the University of Pennsylvania in HEPAfiltered cages and were fed ad libitum. Both male and female mice were used in the study and were sacrificed between the ages of 9-13 weeks. Age-matched litter mates were used as wild type controls.
Feline. The felines were housed in the School of Veterinary Medicine of the University of Pennsylvania. NPC1 mutant diseased felines and their normal counterparts were produced from the same line. The NPC1 felines have a spontaneous missense mutation (C955S) in the NPC1 protein which results in lysosomal accumulation of unesterified cholesterol [9, 10] . At one day of age, peripheral blood leukocytes from blood drawn for the cats were tested by PCR analysis of genomic DNA to determine genotype [27] . Affected and control felines were used between 21 and 25 weeks of age.
Type II Cell and Lamellar Body Isolation
The isolation of type II cells from mice lungs was performed as described previously [28] . Briefly, mice were anesthetized, the chest cavity exposed and the trachea was intubated with a mechanical ventilator to inflate the lungs. The heart was perfused in a saline solution to remove blood cells from the lung. Lungs were filled with saline, excised from the chest cavity, and washed three times with saline to remove macrophages and bronchoalveolar lavage (BAL). An elastase solution was instilled down the trachea, tissue was chopped in a McIlwain TM Tissue Chopper, enzyme was quenched in FBS, and cells were panned on a mouse IgG coated dish to remove macrophages. Later, non-adherent cells were moved to a separate dish and incubated overnight at 37uC. These cells were designated isolated type II cells.
Lamellar bodies were isolated as described previously [29] . Briefly, lungs of 2 to 6 mice or a piece of one lung of a cat were perfused with saline to remove blood cells, rinsed in 0.25 M sucrose, blotted on filter paper, homogenized, filtered through gauze, and pooled. The homogenate was separated on a sucrose gradient, with lamellar body bands appearing between 0.45 and 0.50 M sucrose. Lamellar body containing bands were removed with a glass pipette, the refractive index was measured with a refractometer and the molarity of the fraction was determined. The harvested fraction was diluted to 0.2 M sucrose in water, centrifuged at 20,0006g for 15 minutes. Pellets were stored at 280uC until use.
Western Blotting
Lung tissue from 9-14 week old mice was collected, homogenized, and separated using denaturing sodium dodecyl sulfatepolyacrylamide gel electrophoresis as previously described (8 
Histology & Alveolar Septal Thickness
Lungs from wild type, NPC1 and NPC2 mutant mice were excised from 3 animals for each experimental group. From each mouse, the left lobe, upper right lobe, and lower right lobe were fixed overnight in a mixture of formaldehyde and glutaraldehyde, and embedded in paraffin. Tissue was cut into 5 mm sections and stained with hematoxylin and eosin. Random fields of distal airway were collected at 606 magnification. Alveolar septal thickness was determined using an overlaid test grid. The alveolar septal thickness was measured as the length of a grid line that extended from one alveolus to an adjacent alveolus. Regions containing large airways or capillaries were not included in this measurement. .200 probe ''hits'' of the alveolar septal thickness were gathered from more than 5 sections per mouse and 15 fields for each experimental condition.
Electron Microscopy
Lungs from mice were perfused through the pulmonary artery with 0.1 M sodium cacodylate buffer to remove blood cells. Lungs were excised and fixed by perfusion with 5% glutaraldehyde through the pulmonary artery and trachea. The trachea was removed, and whole lungs were fixed for at least 4 hours. A portion of the lung from a cat were perfused with cacodylate buffer through the bronchi and fixed by immersion in 5% glutaraldehyde. Lungs were cut into 1 mm 3 blocks, treated for 2 hours with 2% osmium, dehydrated, embedded in EPON, and polymerized for 48 hours at 60uC. Blocks were sliced into ultrathin (80 nm) sections in a Leica Ultracut UCT ultramicrotome. Samples were stained with 2% uranyl acetate and 0.5% lead citrate. All samples were imaged on a TEM (100-CX, Jeol).
Measuring Cholesterol and Phospholipid
To measure cholesterol, samples were prepared following instructions in the Amplex Red Cholesterol Assay Kit (Molecular Probes, Eugene, OR, Cat #A-12216). Protein for each corresponding sample was determined using the Lowry assay and data are presented as mg lipid/mg protein [30] . Phospholipid concentration was determined by phosphorus assay [31] . Briefly, the lipid fraction was separated from the water soluble fraction using the Bligh-Dyer method and dried completely in a glass tube [32] . Dried samples were resuspended in 70% perchloric acid (HClO 4 ), heated for 20 minutes, and then cooled. Distilled water and ammonium molybdate were added to the sample and vortexed before the addition of reagent A (amino naphtha sulfonic acid, sodium sulfite, Na meta-Bisulfite). Samples were boiled for 10 minutes, cooled and colorimetric reading was done at 830 nm.
Isolated Lung Perfusion
Uptake and degradation of liposomes labeled with [cholinemethyl- 3 H] dipalmitoyl phosphatidylcholine ([ 3 H]-DPPC) by the isolated, perfused lung was performed as described previously [33] . Briefly, liposomes of DPPC, egg phosphatidylcholine (PC), egg phosphatidylglycerol, and cholesterol (molar ratio of 10:5:2:3) with trace amounts of [ 3 H]-DPPC were prepared by freezing and thawing followed by extrusion under pressure through a 100-mm pore-size filter. The liposomes (10 nmol of DPPC in 20 ml of saline) were instilled into the lungs of anesthetized mice; the lungs were removed and placed in a perfusion apparatus under ventilation. After 5 min (time required for lung isolation, baseline) or 2 hours, the lungs were lavaged and the lung tissue homogenized. The homogenate was extracted [32] and the aqueous and lipid fractions isolated. Phospholipids in the organic phase were fractionated by thin layer chromatography on silica gel plates with chloroform-methanol-ammonia-water (65:35:2.5:2.5, vol/vol) as the solvent system and bands of interest scraped and counted. Disaturated phosphatidylcholine (DSPC) was separated from total PC on a neutral alumina column after osmication of lipids [34] . Unsaturated PC, the product of lysoPC reacylation, was calculated as total dpm in PC minus dpm in disaturated PC (DSPC). Total degradation of internalized DPPC was calculated from the sum of dpm in lysoPC, aqueous, and unsaturated PC after subtraction of the baseline data (5 min).
Immunocytochemistry
Type II cells were fixed in 4% paraformaldehyde for 20 minutes. Cells were washed, fixative was quenched in 0.3% glycine, and cells were permeabilized in 0.2% triton for 30 minutes at room temperature. Cells were blocked in 10% BSA with 2% normal goat serum for 1 hour. Primary antibodies were incubated on cells overnight in dilute blocking buffer. The next day, cells were washed and incubated in secondary antibody for 1 hour. Cells were then washed and imaged. 
Statistics
All data are expressed as mean 6 SEM. Statistical comparisons were performed using SigmaStat (Systat Software, Inc.). Data were analyzed using a Student's t-test or ANOVA. Results were considered statistically significance at P#0.05.
Results
NPC1 and NPC2 mutant mice have average life spans of 72 days [35] and 100 days [26] , respectively. We examined the lung tissue of NPC1 and NPC2 mutant mice by Western blot in homozygous mutant animals near the end of their lifespan (approximately 63-70 days and 84-89 days, respectively). As shown in Fig. 1 , there was no NPC1 or NPC2 protein expression detected in the lung tissue of the respective NPC1 and NPC2 mutant mice kept on a BALB/c background.
Lung Morphology
Histological evaluation of the lungs of NPC1 and NPC2 mutant mice using hematoxylin/eosin stained sections was performed to determine pulmonary effects due to loss of cholesterol transport. The micrographs showed a thickening of the intra-alveolar septae with a slight enlargement of the airways in the NPC1 mice (Fig. 2) . Quantitation of alveolar septum thickness revealed a significant (P,0.05) increase in average thickness in NPC1 (9.160.3 mm, n = 298) and NPC2 (10.860.5 mm, n = 401) mutants compared to wild type mice (5.860.2 mm, n = 421). Both types of NPC mutant mice lung contained ''nests'' of vacuolar filled macrophages and enlarged foamy alveolar macrophages as previously reported for NPC1 mice [6] . At this level, type II cells appeared unremarkable.
Upon closer inspection of the alveolar architecture at the electron microscopic level, more pronounced pulmonary abnormalities were apparent. In Fig. 3 , the wild type (WT) lung demonstrated a normal appearing type II cell (A) and capillary (B) and no macrophages (A) or visible surfactant (C). In contrast, within the NPC1 and NPC2 mouse lungs (Fig. 3, NPC1 , D and NPC2, I) there was surfactant accumulation, a characteristic of alveolar lipidosis (AL). The severe, more pronounced lipid accumulation seen in NPC2 mice (Fig. 3, NPC2, I ), although present in both types, was not as typical as the examples shown in Fig. 3, NPC1 , D or NPC2, O. A detailed assessment of the surfactant accumulation in these mouse models revealed several physical forms which ranged from the striking accumulation of surfactant as tight or loosely packed whirls of phospholipid-like surfactant material in focal areas of the alveolar spaces as seen in the NPC2 mutant mice (Fig. 3, NPC2, N) to the most common form, string-like surfactant (Fig. 3, NPC1 , D and G and NPC2, N and O). In addition there was an accumulation of tubular myelin and surfactant aggregates in large airways (Fig. 3, NPC2 , K) and large surfactant aggregates next to type II cells or in the alveolar space (Fig. 3, NPC2, N) . Proteinaceous-like material in the alveolar space also was found in the lungs of both mice (example in Fig. 3, NPC2, M) .
Within mouse lung capillaries were enlarged polymorphonuclear leukocytes or circulating macrophages filled with vacuolar inclusions were found in both mutant mice, apparent in NPC1 mice Fig. 3D , as reported previously [6] , and NPC2 mice (Fig. 3,  NPC2 , J). Capillary endothelial cells containing enlarged vacuoles/multivesicular bodies (designated by asterisks) were found in both NPC1 (Fig. 3, NPC1 , E,H) and NPC2 (Fig. 3, NPC2 , L) lungs, as previously described [6] in NPC1 mice. In both NPC mutant mice, alveolar macrophages appeared greatly enlarged and vacuole-filled, some with concentric multilamellar electron dense surfactant-like materials (Fig. 3, NPC1 , F, for example). Alveolar macrophages were often found in close contact with type II cells (Fig. 3, NPC1 , E and NPC2, J). The type II cells were marked by the presence of many autophagosomes found in both types of NPC mutant mice (Example from an NPC2 mutant mouse in Fig. 3 , NPC2, P).
Size of Type II Cell Lamellar Bodies
It appeared that the lamellar bodies of type II cells from the affected mice differed in size. Thus, a morphometric analysis of lamellar body size of type II cells was performed for the NPC1 and NPC2 mutant lungs and their matching litter mates using electron microscopic images of the type II cells and ImageJ analysis. The . While some LBs in NPC1 mutant mice showed a distribution similar to wild type, a significant proportion of NPC1 type II cell LBs were enlarged (Fig. 4) 
Abnormal Lipid and Surfactant Protein-A (SP-A) Content of NPC Mutant Mouse Lung
An enrichment in the cholesterol content of NPC1 mouse lungs has been documented previously [24] . The surfactant system of both the NPC1 and NPC2 mice was examined specifically by measuring changes in the phospholipid and cholesterol levels of the lung tissue, surfactant and lamellar bodies. Measurements of the physical parameters of the mice used for the analysis presented in Fig. 5 are shown in Table 1 and were typical for all the mice in the study. The mutant mice had lower body weights than their age-matched littermates. Since the lung weights were similar between groups, the lung weight as a % of total body weight was higher in the NPC mice (Table 1) , as was shown previously for NPC1 mice [8] . The lungs of the mice were lavaged and the surfactant and lavaged lung tissues were processed for lipid and protein content. Lipid analysis of the lungs of the wild type mice demonstrated a minor enrichment of phospholipid and cholesterol in the wild type littermates of the NPC2 mutant mice compared to the littermates of the NPC1 mice, possibly due to the age differences (89 vs. 63 days, respectively) (Fig. 5) ; however, the lungs from both mutant mice showed a significantly elevated lipid content over littermate controls. Both the phospholipid and cholesterol content of the lavaged lung tissue from the NPC1 and NPC2 mutant mice were enriched over their respective controls, as has been shown previously for the cholesterol [8, 24] and phospholipid [8] content of NPC1 mutant mice where the entire lung as an intact organ was examined.
As would be predicted from the lipidosis in the alveolar space observed in the electron microscopic data, there was a marked increase in surfactant phospholipid in both mutant mice. The phospholipid levels of the bronchoalveolar lavage (BAL) were elevated over control mice in the NPC1 mutant (4-fold) and in NPC2 mutant mice (3-fold) (Fig. 5B) , mirroring the abnormal accumulation of surfactant within the alveoli at the EM level (Fig. 3, NPC1, G, and NPC2, I ). Even more striking was the elevation in cholesterol levels, 12-fold in NPC1 (12-fold) and 35-fold in NPC2 mutant BAL (Fig. 5B) . When compared as a ratio, the cholesterol to phospholipid ratio was increased in both NPC1 and NPC2 mutant BAL compared to wild type (Fig. 5B) .
Analysis of the bronchoalveolar lavage showed that the NPC1 mutant mouse lung had a mild protein accumulation which was not the case for the NPC2 mutant mice (Table 1) . We further characterized the lungs of the mutant mice, by analyzing the levels of SP-A, the most abundant surfactant protein. Shown in Fig. 6 is the quantitation (in arbitrary densitometry units) of the amount of SP-A in the lung (normalized to actin) or in the surfactant (with equal protein loading) and expressed relative to wild type samples run on the same gel. SP-A levels were elevated three-fold in the lungs and surfactant of the NPC1 mutant mice compared to agematched wild type. A similar enrichment in SP-A was seen in the lungs of the NPC2 mutant mice. In the NPC2 surfactant, SP-A levels were enhanced but the change did not reach statistical significance.
Lipid analysis was performed on lamellar bodies isolated from pooled samples of lung homogenates, either from NPC1 mutants, NPC2 mutants or the wild type counterparts. The data revealed an increase in phospholipid (2 to2.8-fold increase in both animals) and cholesterol (6.8-fold increase and 7.9-fold increase, respectively) content compared to wild type animals (Fig. 5C) , with a greater increase in cholesterol as shown by the cholesterol to phospholipid ratio. Overall, changes in lung lipid content were comparable between the NPC1 and NPC2 mutant mice, with relatively minor differences.
To determine the effect of lipid enrichment of the lung and lamellar bodies on surfactant uptake and degradation, we utilized the isolated, perfused lung system. 3 H-choline-labelled DPPC liposomes were instilled into the lungs of wild type or NPC1 mutant mice. After a two hour perfusion time, there was no significant difference in the endocytosis of the DPPC by the lungs (5.560.4% for wild type vs. 5.360.3% for NPC1, n = 3). However, total degradation of 3 H-DPPC was reduced by 46% in the NPC1 mice lungs as compared to wild type due to significant decreases in all lipid and aqueous fractions (Fig. 5D) . Thus, the lipid accumulation and the absence of NPC1 protein resulted in a decrease in DPPC degradation.
Cholesterol Accumulation in Lamellar Bodies of Type II Cells of NPC1 Mutant Mice
To validate the biochemical finding of excess cholesterol in lamellar bodies, we examined the cellular distribution of cholesterol in isolated alveolar type II cells using filipin, a fluorescent, free cholesterol-binding probe (Fig. 7A) . In NPC1 mutant type II cells, free cholesterol was apparent within the lumen of lamellar body structures, marked by ATP-binding cassette sub-family A member 3 (ABCA3). NPC2 mutant type II cells had evidence of filipin staining of ABCA3 positive vesicles but the smaller size of the lamellar bodies made intravesicular localization difficult (Fig. 7A) .
Alveolar Macrophages
Alveolar macrophages and type II cells together are responsible for the majority of surfactant turnover, therefore we examined alveolar macrophages from NPC1 and NPC2 mutant mice [36] . Alveolar macrophages isolated from BAL of NPC1 and NPC2 mutant mice were laden with free cholesterol with many large, foamy cells (Fig. 7B ) compared to wild type macrophages. We measured lipid levels in isolated alveolar macrophages and found that phospholipid levels were elevated 6-fold in NPC1 mutant mice, and 2-fold in NPC2 mutant mice. Cholesterol was also elevated 15-fold in NPC1 mutant macrophages and 8-fold in NPC2 mutant macrophages (Fig. 8) .
Feline NPC1 Disease
The disease in affected NPC1 mutant cats is phenotypically, morphologically, and biochemically similar to patients with a mutation in the NPC1 gene and less acute onset [10] . Lung histology revealed thickened septae, foamy leukocytes in the capillaries and evidence of white blood cell infiltrate (Fig. 9) in the affected feline. Analysis of the size of the feline lamellar bodies using ImageJ quantitation of electron micrographs demonstrated a range of sizes surprisingly similar to that seen with mice (Fig. 10) . The area of most of the wild type lamellar bodies ranged between 0.2 and 0.7 micron 2 , while most of the NPC1 mutant feline lamellar bodies were larger than 0.5 micron 2 . Similar to the mice lamellar bodies, the mean size of the NPC1 mutant mice lamellar bodies were 0.9060.03 micron 2 (n = 323 lamellar bodies, 3 cats) versus 0.4060.02 micron 2 (n = 250 lamellar bodies, 3 cats) for wild type feline (P,0.05). Measurement of the lung lipid content (Fig. 10A ) demonstrated a 60% increase in phospholipid and a striking 3.5-fold enrichment in cholesterol. Although the size of the lungs precluded an accurate assessment of the total surfactant lipid, the cholesterol to phospholipid ratio showed a 2.5-fold enrichment in cholesterol over normal feline surfactant (cholesterol/phospholipid ratio: wild type = 0.1160.03, n = 4; NPC1 mut = 0.2860.02, n = 3). The lamellar body phospholipid content did not change while the cholesterol content was elevated by 7-fold (Fig. 10B) . Thus, the NPC1 mutant feline demonstrated lung disease with pathological manifestations comparable to those seen in mice.
Discussion
Our study, using histological, immunological and biochemical procedures, demonstrates that the absence of NPC1 and NPC2 proteins in the lungs of mutant mice on a BALB/c background results in lung disease. Pathologic characteristics at the light microscopic level included thickened intra-alveolar septae, nests of foamy alveolar macrophages and vacuolar-filled circulating leukocytes. Electron microscopic analysis revealed excess surfactant in the alveolar space and capillary endothelial cells with enlarged vacuoles. The type II cells were shown to contain autophagosomes and lamellar bodies of abnormal sizes. Many of Figure 8 . Lipid content of NPC mutant macrophages is elevated. Alveolar macrophages were isolated and cultured as in Fig. 7 . The cells were harvested and the phospholipid and cholesterol content analyzed. W1,W2. Wild type littermates from NPC1 or NPC2 mutant mice, respectively. C1, NPC1; C2, NPC2. The data are mean6SE, n = 4 separate mice. *Statistically significant difference from corresponding wild type littermates. # Significant difference between NPC1 and NPC2 mutant macrophages, P,0.05. doi:10.1371/journal.pone.0067084.g008
the lamellar bodies in NPC1 type II cells were enlarged and the majority in NPC2 type II cells were small. Cholesterol accumulation, a characteristic of the disease in other organ systems, also was found in the various components of the lung surfactant system.
In both the NPC1 and NPC2 mutant mice, the lung tissue, isolated lamellar bodies, surfactant, and alveolar macrophages showed greater that 2-fold enrichment in cholesterol. In conjunction with this change, the phospholipid content of the tissue and Initial reports found NPC1 and NPC2 mutant mice to be essentially identical using criteria such as accumulation of lipids in brain and liver [26] . Likewise, similar pulmonary abnormalities were seen in the lungs of NPC1 and NPC2 mutant mice such as accumulation of foamy, cholesterol-filled macrophages in the alveolar space [2, 6] . However, the lung phenotype is thought to be more severe in the NPC2 mice compared to that reported for NPC1 due to the lack of proteinosis in NPC1 mice, based on histological analysis [37] . Our results, on the other hand, demonstrated that alveolar lipidosis and other pathological changes were at least as severe in the NPC1 mutant mouse compared to the NPC2 hypomorph mouse. The main difference between the two types of NPC disease was the changes in lamellar body size. The more rapid progression of the disease in the NPC1 mouse versus the NPC2 mutant mice has been well documented and serves as a model for the severe infantile onset form of the human disease [26, 38] .
The feline NPC1 disorder, which progresses more slowly, is felt to be an excellent model for the human pathogenesis [9] . Niemann-Pick disease type C felines harbor a single base substitution (2864G-C) resulting in an amino acid change from cysteine to serine (C955S) [9] . The cats demonstrate lysosomal storage disease with hepatic and neurological manifestations including lipid-laden macrophages in the spleen and bone marrow and unesterified cholesterol accumulation in skin fibroblasts [10] . In addition, as shown here, feline NPC1 disease also demonstrated a similar lung phenotype as the Npc1 nih/nih mutant mice. There was thickening of the alveolar walls, foamy capillary leukocytes, and lipid-filled macrophages in the alveolar space. In addition, the feline NPC1 type II cells contained enlarged (occasionally giant) lamellar bodies and lipid-enriched lamellar bodies, surfactant and lung tissue. Thus, both mice and feline animal models are suitable for studies of disease progression and pulmonary complications related to loss of a functioning NPC pathway.
We describe previously uncharacterized dysfunctions in type II cells of the NPC1 and NPC2 mutant mice that may help to clarify their contribution to the elevated surfactant cholesterol phenotype associated with Niemann-Pick type C. First, the surfactant storage organelles, the lamellar bodies, have significantly elevated phospholipid and cholesterol content, which correlate to elevated phospholipid and cholesterol in the surfactant. In support of this data, immunocytochemistry directly demonstrated excess cholesterol accumulated within lamellar bodies of type II cells isolated from the NPC mutant mice. Second, there were anomalies in the lamellar body size in the type II cells from both mutant mice: enlarged lamellar bodies in NPC1 mutant mice, mirrored in the NPC1 mutant felines; and small lamellar bodies in NPC2 mutant mice. The relationship between lamellar body size an pulmonary abnormalities is not yet clear although giant lamellar body formation was associated with impaired surfactant secretion in a mouse model of Hermansky-Pudlak syndrome (HPS) [39] . Thirdly, surfactant phospholipid degradation was inhibited, presumably due to an effect on type II cells as they play a major role in the degradation of surfactant PC [40] . What other alterations in surfactant in surfactant metabolism occur remains to be determined. Our studies highlight the importance of addressing lung epithelial function as a potential underlying cause of lung involvement in NPC disease.
Lamellar body size is an important indication of type II cell health since lamellar body size is altered in a number of genetic diseases such as ABCA3 deficiency and HPS [39, 41, 42] . We have shown the presence of NPC1 and NPC2 in these lysosome-related organelles where they may play a role in the regulation of lamellar body surfactant cholesterol [19] . It is tempting to speculate that the Niemann-Pick C proteins also may play a role in lamellar-body genesis. Lamellar bodies originate as multivesicular bodies that rearrange their internal phospholipid-containing membranes to form larger lamellar bodies [43] . Although the cholesterol content of the lamellar body from NPC mutant mice is high, it is unlikely to be the reason for an enlarged organelle as cholesterol only represents a small fraction of the total lipid. Since two lamellar body populations (small and medium) exist in normal mice while only one population (small) is found in the NPC2 mutant mice, NPC2 may play a role in the formation or maintenance of the medium sized lamellar bodies through its fusinogenic properties [44] . NPC2, located within the lamellar body, may be required for membrane rearrangement of multivesicular bodies, a necessary precedent for formation of larger ''mature'' lamellar bodies while NPC1 could interact with NPC2 and limit fusion. Thus, the absence of NPC2 might result in a lack of fusion and smaller lamellar bodies while the absence of NPC1 would result in unchecked fusion and large lamellar bodies.
The absence of NPC1 protein in mice negatively affected pulmonary function, where inspiratory capacity, elastance and hysterisivity were increased in the diseased lungs [37] . The mechanisms whereby elevation in lung and surfactant cholesterol can result in disruption in the physiology and in the turnover of surfactant are unknown but might include: First, alterations in surfactant properties. Cholesterol is a critical yet understudied component of surfactant that contributes to surface viscosity, such that excess cholesterol interferes with surfactant function [2, 12, 45] . Second, membrane properties may be altered due to the inability of cholesterol to exit the lysosomes and, thus, be unable to reach the plasma membrane, detrimentally affecting plasma membrane lipid rafts, surfactant secretion and endocytic vesicular uptake of surfactant. Finally, free cholesterol accumulation has been implicated in the intensification of oxidative stress and apoptosis, both of which would lead to dysfunction of pneumocyte metabolism [46] .
In summary, we have identified defects in surfactant homeostasis in both NPC1 and NPC2-mutant mice including elevated surfactant phospholipid and cholesterol, elevated lamellar body phospholipid and cholesterol, and abnormal lamellar body sizes. Many of these pathologic changes were noted in the NPC1 mutant feline pulmonary system as well. The work underscores the importance of understanding the regulation of cholesterol trafficking to maintain proper pulmonary function. These studies elucidate novel characteristics of lung disease progression in Niemann-Pick C1 and C2, and demonstrate that epithelial cell dysfunctions can be a contributing source for lung disease.
